BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/10/2022 9:21:28 AM | Browse: 387 | Download: 1076
 |
Received |
|
2022-08-27 14:23 |
|
Peer-Review Started |
|
2022-08-27 14:25 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-09-30 04:56 |
|
Revised |
|
2022-10-06 14:44 |
|
Second Decision |
|
2022-11-03 03:19 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-11-03 20:28 |
|
Articles in Press |
|
2022-11-03 20:28 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-11-04 10:05 |
|
Publish the Manuscript Online |
|
2022-11-10 09:21 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Si-Qi Li, Yang Yang and Lin-Sen Ye |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Guangdong Basic and Applied Basic Research Foundation |
2019A1515110654 |
| National Natural Science Foundation of China |
82103448 |
| China Organ Transplantation Development Foundation |
YZLC-2021-003 |
|
| Corresponding Author |
Lin-Sen Ye, Doctor, MD, PhD, Doctor, Doctor, Postdoc, Surgeon, Department of Hepatic Surgery and Liver Transplantation Center, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Road, Guangzhou 510630, Guangdong Province, China. ye_linsen@163.com |
| Key Words |
Anti-angiogenesis; Immunotherapy; Combination therapy; Vascular endothelial growth factor; Immune checkpoint blockade; Hepatocellular carcinoma |
| Core Tip |
Anti-angiogenesis combined with immunotherapy in hepatocellular carcinoma (HCC) has attracted extensive attention. Although the mechanism of these combinations is largely understood, the biomarkers for predicting treatment response are still lacking. Thus, we outline the relevant mechanism and rationality of the combined application of anti-angiogenics and immune checkpoint inhibitors, and further explore the biomarkers that are associated with treatment response, which are critical in studies of HCC. |
| Publish Date |
2022-11-10 09:21 |
| Citation |
Li SQ, Yang Y, Ye LS. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World J Gastroenterol 2022; 28(42): 6034-6044 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i42/6034.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i42.6034 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
